PubMed Health⌕ Search

Biomedical subjects

A Bardy

Publications and source records attributed to A Bardy.

10 recordsLinked to original sources
PubMed1979

Antipyretic analgesics in patients on antiepileptic drug therapy.

The effect of administration for three days of acetylsalicylic acid (1500 mg/day), phenylbutazone (300 mg/day), paracetamol (1500 mg/day) and tolfenamic acid (300 mg/day) on serum concentrations of phenytoin and carbamazepine were studied in a group of patients on continuous antiepileptic therapy. When measured 10 h after the last dose of the analgesics, the only significant effect was a decrease in total serum phenytoin after three days of phenylbutazone. When six patients on continuous phenytoin therapy took phenylbutazone for two weeks there was at two days an initial decrease, followed by a signficiant increase in total serum phenytoin and a concomitant increase in free phenytoin in serum. Even phenylbutazone was well tolerated by most of the patients. However, its use had to be discontinued on one patient due to obvious signs of phenytoin intoxication, with concomitant increases in the serum free and total phenytoin concentrations.

Adult↗
PubMed1979

Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients.

1. The bioavailability of a brand of phenytoin tablets used in Finland was improved in 1976. In the present retrospective study serum concentrations of phenytoin, measured before and after the change of bioavailability, are compared in 50 epileptic out-patients, who for various reasons used exactly the same dose of phenytoin tablets and of other drugs despite the increased bioavailability of phenytoin. 2. The mean increase of serum phenytoin steady-state concentration was about 70% after the change of bioavailability but there were considerable interindividual differences in the response. The mean increase in serum phenytoin was only 28% in patients with serum phenytoin concentrations 5 microgram/ml or less but the mean increase was 100% in patients with serum phenytoin between 5 and 10 microgram/ml. In patients with serum phenytoin concentrations more than 10 microgram/ml the mean increase in concentration was 60-80% after the improvement of bioavailability. However, in these groups of patients some clinically manifested phenytoin intoxications enforced the patients to the control and to dose reduction obviously before the steady-state concentration of phenytoin was reached. 3. On the basis of our experiences and those reported in the literature some proposals are presented to be considered when the bioavailability of phenytoin or of another drug with a narrow therapeutic range and a dose-dependent kinetics has to be changed.

Biological Availability↗
PubMed1979

Fetal heart rate during a maternal grand mal epileptic seizure.

Although maternal ingestion of antiepileptic drugs is strongly suspected of causing congenital defects, particularly oral clefts, the effect of epilepsy itself or a combined effect of drug intake and epilepsy have not been excluded as etiological factors. Very little is known about fetal oxygenation during a maternal grand mal epileptic seizure. We describe two cases in which fetal heart rate was recorded during a maternal epileptic seizure during labor. The first fetus became clearly asphyctic as judged from the fetal heart rate recording: immediately after the epileptic seizure there was a 13-minute continuous bradycardia wave with decreased short-term variability. After the bradycardia a phase of tachycardia with decreased short-term and long-term variability occurred. In the other fetus there was only a short period of bradycardia, which was followed by a phase of tachycardia and decreased short-term and long-term variability. Both fetuses were vigorous at birth 43 and 87 minutes, respectively, after the epileptic seizures of their mothers. We conclude that a maternal grand mal epileptic seizure can be ominous to the fetus. It is therefore important that epileptic seizures are controlled by optimal medication throughout pregnancy.

Adult↗
PubMed1976

A new stannous agent kit for labelling red blood cells with 99TCM and its clinical application.

99Tcm is chosen for labelling erythrocytes for vascular imaging to take advantage of the physical properties of the radionuclide. A new procedure is described which belongs to the category of pre-treatment methods using a kit. Stannous pyrophosphate is the specific reducing reagent. The technique is easier than already published methods: it consists of adding the above reagent to 2 ml. of heparinized blood, waiting five minutes and discarding the serum after centrifugation, then adding the radioactivity required as 99TcmO4. Labelling yield is superior to 95 per cent. The influence of technetium concentration of the pertechnetate solution on the labeling yield is evaluated and compensated by a slight adjustment of tin concentration when necessary. In vitro and in vivo stability studies show that 99Tcm-labelled red cells are suitable for determination of red cell volume, spleen and placental imaging, particularly in emergencies and in paediatrics.

Blood Volume Determination↗
PubMed1976

Plasma, red cell and cerebrospinal fluid concentrations of myoinositol in patients with severe chronic renal failure.

A study was made of 24 patients with severe chronic renal failure; 14 of them were undergoing regular haemodialysis treatment 3 times weekly. Plasma, red-cell and cerebrospinal fluid concentrations of myoinositol were increased in all the patients treated conservatively. The plasma level of myoinositol correlated with the plasma level of creatinine (r = 0.78). The plasma myoinositol level increased more than the CSF and red-cell levels, indicating that the myoinositol in the red cells and the CSF originated mostly in plasma. Dialysis for eight hours produced a fall of about 50% in the level of myoinositol in plasma while the decrease in red-cell myoinositol was negligible. This lead to an osmotic grandient between extra- and intra-cellular myoinositol which was however small in molar terms and did not correlate with symptoms of central neurological disturbances.

Creatinine↗
PubMed1976

Plasma, red cell and cerebrospinal fluid concentrations of mannitol and sorbital in patients with severe chronic renal failure.

The concentrations of mannitol and sorbitol in plasma, red cells, cerebrospinal fluid and urine were determined in 24 patients with chronic renal failure; 10 of them were on conservative treatment and 14 were haemodialysed three times weekly. The mannitol concentration was significantly increased in the plasma and the cerebrospinal fluid of the uraemic patients compared with the controls. In six out of ten uraemic patients mannitol clearance values exceeded creatinine clearance values. The plasma concentration of sorbitol was undetectable or very low in all patients and control subjects. Red-cell and cerebrospinal fluid concentrations of sorbitol showed a large individual variation in the uraemic patients on conservative treatment and did not correlate with kidney function. During dialysis the mannitol concentration decreased, leading to a small osmotic gradient between the plasma and the red cells. The changes in the concentration of mannitol during dialysis showed no connection with the symptoms of central nervous disturbance which appeared during dialysis treatment. The red cell sorbitol concentration during dialysis increased by about 20%. There was a correlation (p less than 0.05) between t,e increase in sorbital in cereemic patients.

Creatinine↗
PubMed1975

Technetium-99m labeling by means of stannous pyrophosphate: application to bleomycin and red blood cells.

A new technique of technetium labeling using stannous pyrophosphate instead of stannous chloride as reducing agent for pertechnetate has been applied to red blood cells and bleomycin. Results are so encouraging that this technique could be extended to other compounds capable of forming stable complexes with reduced technetium. No saline washes of red cells are necessary before or after the addition of pertechnetate. No purification step is performed after labeling of bleomycin.

Bleomycin↗